Promoter hypermethylation of FBXO32, a novel TGF-β/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer

[1]  D. Matei,et al.  Minireview: epigenetic changes in ovarian cancer. , 2009, Endocrinology.

[2]  H. Su,et al.  An epigenetic marker panel for screening and prognostic prediction of ovarian cancer , 2009, International journal of cancer.

[3]  C. Roberts,et al.  Epigenetics and cancer without genomic instability , 2009, Cell cycle.

[4]  Joel H. Saltz,et al.  BMC Systems Biology , 2022 .

[5]  J. Simon,et al.  Roles of the EZH2 histone methyltransferase in cancer epigenetics. , 2008, Mutation research.

[6]  T. Bagnyukova,et al.  Epigenetic down-regulation of the suppressor of cytokine signaling 1 (Socs1) gene is associated with the STAT3 activation and development of hepatocellular carcinoma induced by methyl-deficiency in rats , 2008, Cell cycle.

[7]  M. Esteller,et al.  Epigenetic biomarkers for human cancer: the time is now. , 2008, Critical reviews in oncology/hematology.

[8]  M. A. Chambers,et al.  TNF induction of atrogin-1/MAFbx mRNA depends on Foxo4 expression but not AKT-Foxo1/3 signaling. , 2008, American journal of physiology. Cell physiology.

[9]  Huaxia Qin,et al.  Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer. , 2008, Neoplasia.

[10]  Feng Su,et al.  The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? , 2008, American journal of obstetrics and gynecology.

[11]  M. Wakabayashi,et al.  The role of cytoreductive/debulking surgery in ovarian cancer. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

[12]  Michiaki Yamashita,et al.  The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. , 2007, The Journal of clinical investigation.

[13]  Qiang Yu,et al.  Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. , 2007, Genes & development.

[14]  P. Leung,et al.  Role of endocrine and growth factors on the ovarian surface epithelium , 2007, The journal of obstetrics and gynaecology research.

[15]  S. Lau,et al.  5-Aza-2′-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation , 2007, Oncogene.

[16]  A. Klein-Szanto,et al.  Phosphorylation-Dependent Ubiquitination of Cyclin D1 by the SCFFBX4-αB Crystallin Complex , 2006 .

[17]  C. Caslini,et al.  Histone modifications silence the GATA transcription factor genes in ovarian cancer , 2006, Oncogene.

[18]  Sandya Liyanarachchi,et al.  Prognostic DNA Methylation Biomarkers in Ovarian Cancer , 2006, Clinical Cancer Research.

[19]  Sandya Liyanarachchi,et al.  Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-alpha responsive promoters. , 2006, Molecular cell.

[20]  S. Gayther,et al.  Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention , 2006, Acta obstetricia et gynecologica Scandinavica.

[21]  藤井 洋.  Fbxw7 contributes to tumor suppression by targeting multiple proteins for ubiquitin-dependent degradation , 2006 .

[22]  A. Klein-Szanto,et al.  Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex. , 2006, Molecular cell.

[23]  Robert Brown,et al.  Hypermethylation of 18S and 28S Ribosomal DNAs Predicts Progression-Free Survival in Patients with Ovarian Cancer , 2005, Clinical Cancer Research.

[24]  J. Issa.  CpG island methylator phenotype in cancer , 2004, Nature Reviews Cancer.

[25]  Da-Zhi Wang,et al.  Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. , 2004, The Journal of clinical investigation.

[26]  W. Leung,et al.  Quantitative detection of methylated SOCS-1, a tumor suppressor gene, by a modified protocol of quantitative real time methylation-specific PCR using SYBR green and its use in early gastric cancer detection , 2004, Biotechnology Letters.

[27]  G. Yancopoulos,et al.  The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. , 2004, Molecular cell.

[28]  J. Benhattar,et al.  Demethylation of the human telomerase catalytic subunit (hTERT) gene promoter reduced hTERT expression and telomerase activity and shortened telomeres. , 2003, Experimental cell research.

[29]  R. Bast,et al.  Epigenetic Regulation of ARHI in Breast and Ovarian Cancer Cells , 2003, Annals of the New York Academy of Sciences.

[30]  D. Fishman,et al.  Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. , 2002, Cancer research.

[31]  Tim Hui-Ming Huang,et al.  Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  M. Skinner,et al.  Role of transforming growth factor β in ovarian surface epithelium biology and ovarian cancer , 2002 .

[33]  M. Skinner,et al.  Role of transforming growth factor beta in ovarian surface epithelium biology and ovarian cancer. , 2002, Reproductive biomedicine online.

[34]  D J Glass,et al.  Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy , 2001, Science.

[35]  K. Nephew,et al.  DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. , 2001, Gynecologic oncology.

[36]  Yoichi Shinkai,et al.  SET Domain-containing Protein, G9a, Is a Novel Lysine-preferring Mammalian Histone Methyltransferase with Hyperactivity and Specific Selectivity to Lysines 9 and 27 of Histone H3* , 2001, The Journal of Biological Chemistry.

[37]  C. Verschraegen,et al.  Anomalies of the TGF-β postreceptor signaling pathway in ovarian cancer cell lines , 2000 .

[38]  C. Verschraegen,et al.  Anomalies of the TGF-beta postreceptor signaling pathway in ovarian cancer cell lines. , 2000, Anticancer research.

[39]  R. L. Baldwin,et al.  Ovarian carcinoma cell cultures are resistant to TGF-beta1-mediated growth inhibition despite expression of functional receptors. , 1999, Gynecologic oncology.

[40]  J. Turchi,et al.  Induction of apoptosis in cisplatin-sensitive and -resistant human ovarian cancer cell lines. , 1997, Cancer research.